Free Trial

Sara Bonstein Sells 57,765 Shares of Insmed, Inc. (NASDAQ:INSM) Stock

Insmed logo with Medical background

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CFO Sara Bonstein sold 57,765 shares of the business's stock in a transaction dated Monday, June 23rd. The shares were sold at an average price of $101.78, for a total transaction of $5,879,321.70. Following the transaction, the chief financial officer now owns 93,536 shares in the company, valued at $9,520,094.08. This represents a 38.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Sara Bonstein also recently made the following trade(s):

  • On Tuesday, June 10th, Sara Bonstein sold 57,766 shares of Insmed stock. The shares were sold at an average price of $89.12, for a total transaction of $5,148,105.92.
  • On Tuesday, June 3rd, Sara Bonstein sold 1,579 shares of Insmed stock. The shares were sold at an average price of $71.50, for a total transaction of $112,898.50.
  • On Wednesday, May 14th, Sara Bonstein sold 1,634 shares of Insmed stock. The shares were sold at an average price of $65.61, for a total transaction of $107,206.74.
  • On Tuesday, May 13th, Sara Bonstein sold 8,870 shares of Insmed stock. The shares were sold at an average price of $67.81, for a total transaction of $601,474.70.

Insmed Price Performance

INSM traded down $2.25 during trading on Friday, reaching $99.49. 34,467,302 shares of the company traded hands, compared to its average volume of 2,309,118. The company has a debt-to-equity ratio of 11.38, a quick ratio of 5.44 and a current ratio of 5.86. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $106.83. The firm has a fifty day simple moving average of $78.01 and a 200 day simple moving average of $75.54. The company has a market cap of $18.87 billion, a P/E ratio of -16.72 and a beta of 0.80.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The company had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. During the same period last year, the business earned ($1.06) earnings per share. The company's quarterly revenue was up 22.9% compared to the same quarter last year. On average, equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Sowell Financial Services LLC purchased a new position in shares of Insmed in the first quarter valued at $255,000. M&T Bank Corp grew its holdings in shares of Insmed by 5.6% in the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock valued at $217,000 after purchasing an additional 166 shares in the last quarter. Truist Financial Corp grew its holdings in shares of Insmed by 3.4% in the fourth quarter. Truist Financial Corp now owns 30,038 shares of the biopharmaceutical company's stock valued at $2,074,000 after purchasing an additional 1,000 shares in the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 411 shares in the last quarter. Finally, Proficio Capital Partners LLC purchased a new position in shares of Insmed in the fourth quarter valued at $1,864,000.

Analyst Ratings Changes

INSM has been the topic of several research analyst reports. Bank of America upped their target price on shares of Insmed from $94.00 to $109.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. Royal Bank Of Canada upped their target price on shares of Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Citigroup upgraded shares of Insmed to a "buy" rating in a research note on Tuesday, June 10th. Morgan Stanley increased their price objective on shares of Insmed from $90.00 to $102.00 and gave the stock an "overweight" rating in a research note on Wednesday, June 11th. Finally, Leerink Partners increased their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, June 10th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $106.80.

View Our Latest Stock Report on Insmed

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Should You Invest $1,000 in Insmed Right Now?

Before you consider Insmed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.

While Insmed currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines